EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Claudin 1, 4, 6 and 18 isoform 2 as targets for the treatment of cancer (Review)

Masuko Katoh, Masaru Katoh

International Journal of Molecular Medicine · 13.09.2024 · 54 (5)

DOI: 10.3892/ijmm.2024.5424 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Medicine, online erschienen am 13.09.2024. Verfasst von Masuko Katoh und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Global Network, M & M Precision Medicine, Tokyo 113‑0033, Japan. Hauptthemen laut MEDLINE: Claudins, Neoplasms. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 134 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The 24 claudin (CLDN) genes in the human genome encode 26 representative CLDN family proteins. CLDNs are tetraspan‑transmembrane proteins at tight junctions. Because several CLDN isoforms, such as CLDN6 and CLDN18.2, are specifically upregulated in human cancer, CLDN‑targeting monoclonal antibodies (mAbs), antibody‑drug conjugates (ADCs), bispecific antibodies (bsAbs) and chimeric antigen receptor (CAR) T cells have been developed. In the present review, CLDN1‑, 4‑, 6‑ and 18.2‑targeting investigational drugs in clinical trials are discussed. CLDN18.2‑directed therapy for patients with gastric and other types of cancer is the most advanced area in this field. The mouse/human chimeric anti‑CLDN18.2 mAb zolbetuximab has a single‑agent objective response rate (ORR) of 9%, and increases progression‑free and overall survival in combination with chemotherapy. The human/humanized anti‑CLDN18.2 mAb osemitamab, and ADCs AZD0901, IBI343 and LM‑302, with single‑agent ORRs of 28‑60%, have been tested in phase III clinical trials. In addition, bsAbs, CAR T cells and their derivatives targeting CLDN4, 6 or 18.2 are in phase I and/or II clinical trials. AZD0901, IBI343, zolbetuximab and the anti‑CLDN1 mAb ALE.C04 have been granted fast track designation or priority review designation by the US Food and Drug Administration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClaudinsNeoplasmsHumansAnimalsProtein IsoformsMolecular Targeted TherapyClaudin-4Claudin-1Antibodies, MonoclonalAntineoplastic Agents

Stichwörter der Autor:innen

TGF‑βWNTepithelial‑mesenchymal transitionfibroblast growth factor receptorimmunosuppressive tumor microenvironmentintratumor heterogeneitynon‑small cell lung cancerovarian cancerpancreatic cancersplicing variant

Substanzen

ClaudinsProtein IsoformsClaudin-4Claudin-1Antibodies, MonoclonalCLDN18 protein, humanclaudin 6Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Global Network, M & M Precision Medicine, Tokyo 113‑0033, Japan.

Zitieren

APA

Katoh, M., & Katoh, M. (2024). Claudin 1, 4, 6 and 18 isoform 2 as targets for the treatment of cancer (Review). International Journal of Molecular Medicine, 54(5). https://doi.org/10.3892/ijmm.2024.5424

Vancouver

Katoh M, Katoh M. Claudin 1, 4, 6 and 18 isoform 2 as targets for the treatment of cancer (Review). International Journal of Molecular Medicine. 2024;54(5). doi:10.3892/ijmm.2024.5424

BibTeX
@article{Katoh2024,
  author = {Katoh, Masuko and Katoh, Masaru},
  title = {Claudin 1, 4, 6 and 18 isoform 2 as targets for the treatment of cancer (Review)},
  journal = {International Journal of Molecular Medicine},
  year = {2024},
  volume = {54},
  number = {5},
  doi = {10.3892/ijmm.2024.5424}
}
Kostenlos starten →